共 169 条
- [1] Goodsaid FM(2010)Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact Nat Rev Drug Discov 9 435-45
- [2] Amur S(2007)An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA’s critical path initiative Drug Discov Today Technol 4 3-8
- [3] Aubrecht J(2015)Genomics in the land of regulatory science Regul Toxicol Pharmacol 72 102-6
- [4] Burczynski ME(2010)The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models Nat Biotechnol 28 827-38
- [5] Carl K(2010)An interactive effect of batch size and composition contributes to discordant results in GWAS with the CHIAMO genotyping algorithm Pharmacogenomics J 10 355-63
- [6] Catalano J(2010)Consistency of predictive signature genes and classifiers generated using different microarray platforms Pharmacogenomics J 10 247-57
- [7] Tong W(2010)Assessing sources of inconsistencies in genotypes and their effects on genome-wide association studies with HapMap samples Pharmacogenomics J 10 364-74
- [8] Harris SC(2010)Genomic indicators in the blood predict drug-induced liver injury Pharmacogenomics J 10 267-77
- [9] Fang H(2010)A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data Pharmacogenomics J 10 278-91
- [10] Shi L(2010)Variability in GWAS analysis: the impact of genotype calling algorithm inconsistencies Pharmacogenomics J 10 324-35